Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy

Vinay K Belwal,1 KP Singh1,2 1Bio-Nanotechnology Research Laboratory, Biophysics Unit, CBSH, GB Pant University Agriculture and Technology, Pantnagar, Uttarakhand, 2Department of Molecular Biology, Biotechnology & Bioinformatics, COBSH, CCS Haryana Agriculture University, Hisar, Haryana, In...

Full description

Bibliographic Details
Main Authors: Belwal VK, Singh KP
Format: Article
Language:English
Published: Dove Medical Press 2018-03-01
Series:International Journal of Nanomedicine
Subjects:
Online Access:https://www.dovepress.com/nanosilica-supported-liposome-protocells-as-a-drug-vehicle-for-cancer--peer-reviewed-article-IJN
_version_ 1818571188953153536
author Belwal VK
Singh KP
author_facet Belwal VK
Singh KP
author_sort Belwal VK
collection DOAJ
description Vinay K Belwal,1 KP Singh1,2 1Bio-Nanotechnology Research Laboratory, Biophysics Unit, CBSH, GB Pant University Agriculture and Technology, Pantnagar, Uttarakhand, 2Department of Molecular Biology, Biotechnology & Bioinformatics, COBSH, CCS Haryana Agriculture University, Hisar, Haryana, India Abstract: This study encompasses the development and comparison of nanosilica-supported liposome (protocells), conventional liposome, and polyethylene glycol (PEG)-liposome. An effort was made to study the drug encapsulation efficiency and the in vitro release of the drug, and whether protocells (nanovesicles) could sustain the release of the drug by increasing the residence time, which could reduce the dose-related systemic toxicity of the drug, that is, vincristine sulfate. Nanovesicles had a good encapsulation efficiency (71%), which was comparable to the conventional and PEG-liposome, which were 74% and 78%, respectively. The obtained vesicles were in the size range 100–150 nm, and the drug release efficiency of conventional, PEGylated, and protocells liposome was about 67%, 42%, and 52%, respectively, in 150 minutes. The intermediate value of nanosilica-supported liposome indicates the ability for stable and controlled release of the drug, which prevents the rapid burst or slower release of the drug. This study reveals that protocells as nanovesicles could be a better choice for the delivery of cancer drugs such as vincristine sulfate. Keywords: mesoporous silica nanoparticles, nanovesicles, protocells, nanodimensions, nanosilica supported liposomes
first_indexed 2024-12-14T13:52:28Z
format Article
id doaj.art-f8346970fdb94c74acbb919a68cf8e71
institution Directory Open Access Journal
issn 1178-2013
language English
last_indexed 2024-12-14T13:52:28Z
publishDate 2018-03-01
publisher Dove Medical Press
record_format Article
series International Journal of Nanomedicine
spelling doaj.art-f8346970fdb94c74acbb919a68cf8e712022-12-21T22:59:01ZengDove Medical PressInternational Journal of Nanomedicine1178-20132018-03-01Volume 1312512737270Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapyBelwal VKSingh KPVinay K Belwal,1 KP Singh1,2 1Bio-Nanotechnology Research Laboratory, Biophysics Unit, CBSH, GB Pant University Agriculture and Technology, Pantnagar, Uttarakhand, 2Department of Molecular Biology, Biotechnology & Bioinformatics, COBSH, CCS Haryana Agriculture University, Hisar, Haryana, India Abstract: This study encompasses the development and comparison of nanosilica-supported liposome (protocells), conventional liposome, and polyethylene glycol (PEG)-liposome. An effort was made to study the drug encapsulation efficiency and the in vitro release of the drug, and whether protocells (nanovesicles) could sustain the release of the drug by increasing the residence time, which could reduce the dose-related systemic toxicity of the drug, that is, vincristine sulfate. Nanovesicles had a good encapsulation efficiency (71%), which was comparable to the conventional and PEG-liposome, which were 74% and 78%, respectively. The obtained vesicles were in the size range 100–150 nm, and the drug release efficiency of conventional, PEGylated, and protocells liposome was about 67%, 42%, and 52%, respectively, in 150 minutes. The intermediate value of nanosilica-supported liposome indicates the ability for stable and controlled release of the drug, which prevents the rapid burst or slower release of the drug. This study reveals that protocells as nanovesicles could be a better choice for the delivery of cancer drugs such as vincristine sulfate. Keywords: mesoporous silica nanoparticles, nanovesicles, protocells, nanodimensions, nanosilica supported liposomeshttps://www.dovepress.com/nanosilica-supported-liposome-protocells-as-a-drug-vehicle-for-cancer--peer-reviewed-article-IJNMesoporous silica nanoparticlesnanovesiclesprotocellsNano dimensions
spellingShingle Belwal VK
Singh KP
Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
International Journal of Nanomedicine
Mesoporous silica nanoparticles
nanovesicles
protocells
Nano dimensions
title Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
title_full Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
title_fullStr Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
title_full_unstemmed Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
title_short Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
title_sort nanosilica supported liposome protocells as a drug vehicle for cancer therapy
topic Mesoporous silica nanoparticles
nanovesicles
protocells
Nano dimensions
url https://www.dovepress.com/nanosilica-supported-liposome-protocells-as-a-drug-vehicle-for-cancer--peer-reviewed-article-IJN
work_keys_str_mv AT belwalvk nanosilicasupportedliposomeprotocellsasadrugvehicleforcancertherapy
AT singhkp nanosilicasupportedliposomeprotocellsasadrugvehicleforcancertherapy